Vascular endothelial growth factor inhibitors (VEGFIs) have transformed treatment paradigms for several malignancies. By ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Biocon Biologics, a subsidiary of India-based Biocon Ltd, said on Thursday that U.S. FDA has approved Jobevne, a biosimilar ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...

Jobevne is a recombinant humanised monoclonal antibody which functions as a vascular endothelial growth factor inhibitor, ...

Anemia is a common condition in premature infants, particularly those at risk for retinopathy of prematurity (ROP).

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon Biologics' Jobevne, a biosimilar of Avastin, approved by the FDA, expanding oncology portfolio and access to ...

Government has allocated A$180,000 ($108,079) to improve treatment and support for individuals affected by macular disease.